Inteliphage and the EIC Accelerator: A Phage Test Still Unproven

Vésale Bioscience, founded in Belgium in 2018 and since renamed Inteliphage, works on personalised phage therapy, which uses bacteriophages, viruses that infect bacteria, to treat infections that antibiotics no longer cure. Its EIC project was to industrialise the "Phagogram", described as "the first automated in-vitro diagnostic tool that enables a fast determination of bacteriophages suitable for treating a particular bacterial infection", testing up to 96 phages "within 2-3 hours", according to CORDIS.

The European Innovation Council granted €1,800,000 towards a €3.10 million project from February 2023 to October 2025. The final report says that during verification in 2024, "main values for the sensitivity of the test were unacceptable and made the validation phase impossible", which it blames on "the total absence of standards, norms and guidelines". After developing its own reference methods, the company says precision, robustness and sensitivity now exceed 90%, and that final validation is "planned Q2-Q3 - 2026" before CE marking as an in-vitro diagnostic.

Where Inteliphage Stands Now

Inteliphage's website says it is "developing PhageXpert", an automated phage susceptibility workflow, and building a phage supply capability and curated library. In September 2026 it announced a partnership with the University of Birmingham's Precision Health Technologies Accelerator to continue developing PhageXpert. It joined the BEAM Alliance of European antimicrobial resistance companies in December 2025. No CE marking has been announced.

The Technology: Matching Phages to Bacteria in Hours

A disposable well plate holds a collection of fixed phages; the patient's bacteria are added and a luminometer measures each phage's activity against them, with software proposing the best cocktail. The report says fixed phage cocktails have shown only 20% to 30% efficiency in clinical trials, while personalised preparations have exceeded 85% success in case reports. Between the application and the final report, the promised capacity fell from up to 96 phages to up to 25, and the time rose from 2 to 3 hours to 3 to 4 hours.

What the EIC Project Promised, and What CORDIS Shows

The project was to industrialise the Phagogram, validate it clinically in European hospitals and prepare it for market. Industrial development and software were done, but clinical validation could not start on schedule. At the project's end the test was ready only to begin final validation. CORDIS lists the project as closed.

1. Industrial developmentDeliveredPer final report.
2. Test performanceDeliveredAbove 90%, after rework.
3. Clinical validationNot donePlanned for 2026.
4. CE markingNot doneAfter validation.

The Money

Inteliphage lost between €0.75 million and €2.02 million a year from 2022 to 2025, according to Companyweb. It reported turnover for the first time in 2025, €22,546. Its balance sheet grew to €12.6 million, with debts of €9.45 million and equity of €3.19 million. Its articles and capital were amended in January 2026.

What Cannot Be Checked

Why Europe Should Care

Inteliphage cites WHO estimates that drug-resistant infections are linked to nearly 5 million deaths a year. Phage therapy could help where antibiotics fail, but only if doctors can quickly pick the right phages. The EIC funded that missing step; it is not finished.

The Verdict

Inteliphage and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.